0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Sugar-sweetened beverages, low/no-calorie beverages, fruit juice and non-alcoholic fatty liver disease defined by fatty liver index: the SWEET project

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Sweetened beverage intake may play a role in non-alcoholic fatty liver disease (NAFLD) development, but scientific evidence on their role is limited. This study examined associations between sugar-sweetened beverages (SSB), low/no-calorie beverages (LNCB) and fruit juice (FJ) intakes and NAFLD in four European studies.

          Methods

          Data for 42,024 participants of Lifelines Cohort, NQPlus, PREDIMED-Plus and Alpha Omega Cohort were cross-sectionally analysed. NAFLD was assessed using Fatty Liver Index (FLI) (≥60). Restricted cubic spline analyses were used to visualize dose–response associations in Lifelines Cohort. Cox proportional hazard regression analyses with robust variance were performed for associations in individual cohorts; data were pooled using random effects meta-analysis. Models were adjusted for demographic, lifestyle, and other dietary factors.

          Results

          Each additional serving of SSB per day was associated with a 7% higher FLI-defined NAFLD prevalence (95%CI 1.03–1.11). For LNCB, restricted cubic spline analysis showed a nonlinear association with FLI-defined NAFLD, with the association getting stronger when consuming ≤1 serving/day and levelling off at higher intake levels. Pooled Cox analysis showed that intake of >2 LNCB servings/week was positively associated with FLI-defined NAFLD (PR 1.38, 95% CI 1.15–1.61; reference: non-consumers). An inverse association was observed for FJ intake of ≤2 servings/week (PR 0.92, 95% CI: 0.88–0.97; reference: non-consumers), but not at higher intake levels. Theoretical replacement of SSB with FJ showed no significant association with FLI-defined NAFLD prevalence (PR 0.97, 95% CI 0.95–1.00), whereas an adverse association was observed when SSB was replaced with LNCB (PR 1.12, 95% CI 1.03–1.21).

          Conclusions

          Pooling results of this study showed that SSB and LNCB were positively associated with FLI-defined NAFLD prevalence. Theoretical replacement of SSB with LNCB was associated with higher FLI-defined NAFLD prevalence. An inverse association was observed between moderate intake of FJ and FLI-defined NAFLD. Our results should be interpreted with caution as reverse causality cannot be ruled out.

          Related collections

          Most cited references57

          • Record: found
          • Abstract: found
          • Article: not found

          Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

          Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic steatohepatitis (NASH). PubMed/MEDLINE were searched from 1989 to 2015 for terms involving epidemiology and progression of NAFLD. Exclusions included selected groups (studies that exclusively enrolled morbidly obese or diabetics or pediatric) and no data on alcohol consumption or other liver diseases. Incidence of hepatocellular carcinoma (HCC), cirrhosis, overall mortality, and liver-related mortality were determined. NASH required histological diagnosis. All studies were reviewed by three independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication, and study population. We used random-effects models to provide point estimates (95% confidence interval [CI]) of prevalence, incidence, mortality and incidence rate ratios, and metaregression with subgroup analysis to account for heterogeneity. Of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa. Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05). Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12). HCC incidence among NAFLD patients was 0.44 per 1,000 person-years (range, 0.29-0.66). Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80). Incidence risk ratios for liver-specific and overall mortality for NAFLD were 1.94 (range, 1.28-2.92) and 1.05 (range, 0.70-1.56).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

            A cluster of risk factors for cardiovascular disease and type 2 diabetes mellitus, which occur together more often than by chance alone, have become known as the metabolic syndrome. The risk factors include raised blood pressure, dyslipidemia (raised triglycerides and lowered high-density lipoprotein cholesterol), raised fasting glucose, and central obesity. Various diagnostic criteria have been proposed by different organizations over the past decade. Most recently, these have come from the International Diabetes Federation and the American Heart Association/National Heart, Lung, and Blood Institute. The main difference concerns the measure for central obesity, with this being an obligatory component in the International Diabetes Federation definition, lower than in the American Heart Association/National Heart, Lung, and Blood Institute criteria, and ethnic specific. The present article represents the outcome of a meeting between several major organizations in an attempt to unify criteria. It was agreed that there should not be an obligatory component, but that waist measurement would continue to be a useful preliminary screening tool. Three abnormal findings out of 5 would qualify a person for the metabolic syndrome. A single set of cut points would be used for all components except waist circumference, for which further work is required. In the interim, national or regional cut points for waist circumference can be used.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

                Bookmark

                Author and article information

                Contributors
                edith.feskens@wur.nl
                Journal
                Nutr Diabetes
                Nutr Diabetes
                Nutrition & Diabetes
                Nature Publishing Group UK (London )
                2044-4052
                21 April 2023
                21 April 2023
                2023
                : 13
                : 6
                Affiliations
                [1 ]GRID grid.4818.5, ISNI 0000 0001 0791 5666, Division of Human Nutrition and Health, , Wageningen University and Research, ; Wageningen, the Netherlands
                [2 ]GRID grid.5841.8, ISNI 0000 0004 1937 0247, Nutrition Research Foundation, , Barcelona Science Park, ; Barcelona, Spain
                [3 ]GRID grid.12295.3d, ISNI 0000 0001 0943 3265, Center of Research on Psychological Disorders and Somatic Diseases (CORPS) Department of Medical and Clinical Psychology, , Tilburg University, ; Tilburg, the Netherlands
                [4 ]GRID grid.9435.b, ISNI 0000 0004 0457 9566, Institute for Food, Nutrition and Health, , University of Reading, ; Berkshire, UK
                [5 ]GRID grid.10025.36, ISNI 0000 0004 1936 8470, Department of Psychology, , University of Liverpool, ; Liverpool, UK
                [6 ]GRID grid.9909.9, ISNI 0000 0004 1936 8403, School of Psychology, , University of Leeds, ; Leeds, UK
                [7 ]GRID grid.5254.6, ISNI 0000 0001 0674 042X, Department of Nutrition, Exercise, and Sports, Faculty of Science, , University of Copenhagen, ; Copenhagen, Denmark
                [8 ]GRID grid.4973.9, ISNI 0000 0004 0646 7373, Clinical Research, , Copenhagen University Hospital – Steno Diabetes Center Copenhagen, ; Herlev, Denmark
                [9 ]GRID grid.467039.f, ISNI 0000 0000 8569 2202, Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Preventive Medicine Service, Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), , Canarian Health Service, ; Las Palmas, Spain
                [10 ]GRID grid.413448.e, ISNI 0000 0000 9314 1427, Centro de Investigación Biomédica en Red Fisiopatologia de la Obesidad y la Nutrición (CIBEROBN), , Institute of Health Carlos III, ; Madrid, Spain
                Author information
                http://orcid.org/0000-0001-8141-4907
                http://orcid.org/0000-0002-4554-6184
                http://orcid.org/0000-0001-5229-4491
                http://orcid.org/0000-0001-7638-0589
                http://orcid.org/0000-0002-9658-9061
                http://orcid.org/0000-0001-5819-2488
                Article
                237
                10.1038/s41387-023-00237-3
                10121594
                37085478
                610ad53a-c040-4b8b-b622-fe68445b0ca2
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 18 August 2022
                : 30 March 2023
                : 6 April 2023
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100000780, European Commission (EC);
                Award ID: 774293
                Award ID: 774293
                Award ID: 774293
                Award ID: 774293
                Award ID: 774293
                Award ID: 774293
                Award ID: 774293
                Award ID: 774293
                Award ID: 774293
                Award ID: 774293
                Award ID: 774293
                Award ID: 774293
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2023

                Endocrinology & Diabetes
                metabolic syndrome,diabetes
                Endocrinology & Diabetes
                metabolic syndrome, diabetes

                Comments

                Comment on this article